Metformin Hydrochloride Enteric-coated Capsules

Metformin hydrochloride is a hypoglycemic drug that improves blood sugar tolerance in patients with type 2 diabetes and reduces basal and postprandial blood sugar. The mechanism of action of metformin hydrochloride is different from other types of oral anti-glycemic drugs. It can reduce the production of glycogen, reduce intestinal absorption of sugar, and increase insulin sensitivity by increasing peripheral sugar uptake and utilization. Unlike sulfonylurea drugs, metformin hydrochloride will not cause hypoglycemia in patients with type 2 diabetes or patients with normal blood sugar (except for special circumstances, see precautions). After treatment with metformin hydrochloride, insulin secretion remains unchanged, while fasting insulin levels and daily plasma insulin levels are reduced.

Metformin hydrochloride.

The content of this product is white to off-white enteric-coated microcapsules.

1. This product is first used for type 2 diabetes that is ineffective with simple diet control and physical exercise, especially obese type 2 diabetes. 2. For type 1 or type 2 diabetes, this product can be used in combination with insulin to increase the blood sugar lowering effect of insulin, reduce insulin dosage, and prevent hypoglycemia. 3. This product can also be used in combination with sulfonylurea oral hypoglycemic drugs to have a synergistic effect.

It should be taken according to the doctor's advice. The general starting dose for adults is 0.25g (1 tablet) at a time, twice a day, before meals. After about a week, if the condition is not well controlled, it can be increased to 3 times a day, 0.25g (1 tablet) each time, and the dosage can be adjusted according to the efficacy. The daily dosage should not exceed 1.8g

Common adverse reactions of this product include diarrhea, nausea, vomiting, bloating, fatigue, indigestion, abdominal discomfort and headache. Other rare adverse reactions include abnormal stool, hypoglycemia, myalgia, dizziness, abnormal nails, rash, increased sweating, abnormal taste, chest discomfort, chills, flu symptoms, hot flashes, palpitations, weight loss, etc. Metformin can reduce the absorption of vitamin B12, but rarely causes anemia. It is rare for this product to cause lactic acidosis within the therapeutic dose range.

1. Contraindicated in patients with kidney disease or the following conditions: renal dysfunction caused by heart failure (shock), acute myocardial infarction and sepsis (serum creatinine level ≥1.5 mg/dL (male), ≥1.4 mg/dL (female) or abnormal creatinine clearance) 2. Congestive heart failure requiring drug treatment, and other serious heart and lung diseases. 3. Severe infection and trauma, surgical operation, clinical hypotension and hypoxia, etc. 4. Known allergy to metformin hydrochloride. 5. Acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, and diabetic ketoacidosis requiring insulin treatment. 6. Alcoholics. 7. Patients who receive intravascular injection of iodinated contrast agents should temporarily stop using this product. 8. Patients with uncorrected vitamin B12 and folic acid deficiency.

Precautions for children: The maximum daily dose of this product for patients with type 2 diabetes aged 10 to 16 years is 2000 mg. This product is not recommended for children under 10 years old. Precautions for pregnancy and lactation: This product is not recommended for pregnant women. Lactating women should use this product with caution. If this product must be used, breastfeeding should be stopped. Precautions for the elderly: When elderly patients over 65 years old use metformin, they should be cautious and have their renal function checked regularly. The maximum dose is usually not used. This product is not recommended for patients over 80 years old unless the creatinine clearance test shows that renal function is not reduced.

1. Single-dose combined use of metformin and glibenclamide did not change the pharmacokinetic parameters of metformin. 2. When metformin was used in combination with furosemide (furosemide), the AUC of metformin increased, but renal clearance did not change; at the same time, the C. and AUC of furosemide decreased, the terminal half-life was shortened, and renal clearance did not change. 3. Cationic drugs secreted by the renal tubules (such as amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim and vancomycin) may theoretically compete with metformin for the renal tubular transport system and interact with each other. Therefore, it is recommended to closely monitor and adjust the dose of this product and/or interacting drugs. 4. When metformin was used in combination with cimetidine, the plasma and whole blood AUC of metformin increased, but the elimination half-life of metformin did not change when the two drugs were used in combination as a single dose. The pharmacokinetics of cimetidine did not change. 5. If you take certain drugs that can cause blood sugar to rise at the same time, such as thiazides or other diuretics, glucocorticoids, phenothiazines, thyroid preparations, hormones, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid, you should monitor blood sugar closely, and pay close attention to the occurrence of hypoglycemia after these drugs are discontinued. 6. Metformin does not bind to plasma proteins, so drugs that are highly bound to proteins, such as salicylates, sulfonamides, chloranil, probenecid, etc., are less likely to interact with sulfonylurea drugs, which are mainly bound to serum proteins. 7. Except for chlorpropamide, patients usually do not need a conversion period when switching from other oral hypoglycemic drugs to this product. Patients taking chlorpropamide should pay close attention to the first 2 weeks of switching to this product, because chlorpropamide has a long retention in the body, which can easily lead to drug overdose and hypoglycemia. 8. Metformin has a tendency to increase the anticoagulant effect of warfarin. 9. Taking resin drugs together with this product can reduce the absorption of metformin.

Keep in a dark place and sealed (10~30 degrees).

0.25 g

36 months

Zhuhai Rundu Pharmaceutical Co., Ltd.

• Founded in:

  1999-12-30

• Address:

  No. 6, Airport North Road, Sanzao Town, Jinwan District, Zhuhai City

• Tax NO.:

  91440400192520640G

• Registered Funds:

  334.893286 million yuan

• Website:

  Log in to view

• Email:

  Log in to view